SMO and skin basal cell carcinoma: In particular, GDC-0449 (Vismodegib/ErivedgeTM), an SMO antagonist, entered clinical trials and was approved in January 2012 by the FDA for the treatment of adults with locally advanced or metastatic BCC who cannot be treated with surgery or radiation [37].